Clear Science From Cleerly

February is American Heart Month, and Cleerly wants to Cleer the Air on proven heart disease prevention and treatment methods. Heart disease remains the #1 public health epidemic in the world, causing one death every 1.7 seconds, and yet traditional methods of heart disease measure indirect markers of disease instead of the actual disease - atherosclerosis (plaque).

Cleerly-Heart_Month-LP_Header-XL

 

Throughout the month, we'll discuss the science behind our new standard of care that is transforming the evaluation of heart disease through precision heart care that measures plaque. Our approach applies advanced artificial intelligence (AI) technology to non-invasive computed tomography (CT) scans to provide physicians and patients with a heart attack prevention approach that is more personalized and proactive than historical methods.

Learn how we are halting the progression of heart disease, dramatically improving clinical outcomes, and drastically reducing the costs associated with cardiovascular care.

Sign up to receive Cleerly science on heart disease prevention.

 

Subscribe

 

Follow Cleerly Science

Connect with us on Twitter and LinkedIn, and join us here as we roll out new heart content daily for the entire month of February.

 

Cleerly's Latest News

Cleerly’s groundbreaking CLARIFY 2 study echo the recent ACC guidelines on the use of CCTA for non-invasive heart disease evaluation.
Learn More
CLARIFY2 - Discordant Case Example
In 1964, U.S. President Lyndon B. Johnson declared the first #heartmonth. Ever since, U.S. presidents have continued the tradition.
View This Year's Proclamation
In 1964, U.S. President Lyndon B. Johnson declared the first #heartmonth.
Current methods mis 70% of all patients who will suffer a heart attack, as they are mistakenly considered
CLARIFY2 affirms Cleerly AI-enabled CCTA over existing, invasive heart disease assessment methods.
Clinical trials with Cleerly have shown the ability to: detect high-risk plaque in 58% more patients than human readers, reduce referrals for unnecessary procedures, and affirm the value of CCTA over invasive methods.
Our founder and CEO Dr. James Min joined Omar Ford on the Let’s Talk Medtech podcast.
Listen to the Podcast
Cleerly CEO and Founder Dr. James Min on the Let's Talk Medtech podcast
Cleerly's AI-guided approach to CCTA found 58% more high-risk plaque than the consensus of 3 expert readers.
FLPiR2mVUAw1rER
American Heart Month has arrived and we’re releasing new innovations that up the ante in precision heart care.
Learn More
Cleerly v2.2.0 Release
Cleer the Air - Heart disease kills the equivalent of 9 fully-loaded 737s each day in America.
#GoRedforWomen | Join Cleerly as we encourage women to take charge of their heart health.
Go Red for Women
Are you wearing red today? The Cleerly team is!
Cleer the Air - Heart disease killed nearly 700,000 Americans in 2020 - February 03, 2022
Cleerly Recognized as NYC Digital Health 100
Learn More
NYC_HBL-Digital_Health_100-LP_Card
Envisioning a World Without Heart Attacks
Read More
Generational Heart- Disease - Grandmother and Granddaughter
 

More Heart Month Resources

 

Connect With Us to Learn More

Subscribe to receive Cleerly news, product information, and upcoming events. 

 

Subscribe

Patents

Cleerly continues to revolutionize heart attack and cardiovascular disease prevention and treatment everyday by inventing world-class technology. Cleerly invests significant time and resources in research and development towards this goal. To protect Cleerly’s research and development efforts, Cleerly has vigorously developed a robust intellectual property portfolio – all part of a strategy for protecting the innovations that make Cleerly an industry leader in cardiovascular disease prevention and treatment.

Cleerly’s products and services may be covered by or for use under one or more of U.S. Patent Nos. 12,245,882, 12,144,669, 11,922,627, 11,948,301, 11,861,833, 11,967,078, 12,141,976, 11,210,786, 11,232,564, 11,276,170, 11,288,799, 11,302,001, 11,315,247, 11,367,190, 11,690,586, 11,751,826, 11,779,292, 11,832,982, 11,969,280, 12,193,862, 11,094,061, 11,094,060, 11,113,811, 11,120,550, 11,120,549, 11,132,796, 11,238,587, 11,244,451, 11,302,002, 11,308,617, 11,321,840, 11,341,644, 11,501,436, 11,660,058, 11,672,497, 11,730,437, 11,737,718, 11,751,830, 11,751,829, 11,766,230, 11,766,229, 11,896,415, 12,023,190, 12,076,175, 12,097,063, 12,156,759, 12,171,606, 12,178,627, 10,813,612, 11,317,883, 11,350,899, 11,642,092, 11,751,831, 11,759,161, and 12,138,093, as well as other patents that are pending.

For additional information, please contact legal@cleerlyhealth.com.

Solutions
About

© 2025 Cleerly, Inc.